Page last updated: 2024-11-02

pioglitazone and HIV Lipodystrophy Syndrome

pioglitazone has been researched along with HIV Lipodystrophy Syndrome in 6 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Research Excerpts

ExcerptRelevanceReference
"Highly active antiretroviral therapy (HAART)-induced lipoatrophy is characterized by hypoleptinemia and insulin resistance."9.15Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. ( Brennan, A; Doweiko, J; Kang, ES; Karchmer, AW; Magkos, F; Mantzoros, CS; Sweeney, L, 2011)
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance."7.72Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004)
"Highly active antiretroviral therapy (HAART)-induced lipoatrophy is characterized by hypoleptinemia and insulin resistance."5.15Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study. ( Brennan, A; Doweiko, J; Kang, ES; Karchmer, AW; Magkos, F; Mantzoros, CS; Sweeney, L, 2011)
" Pioglitazone is an oral antidiabetic agent that acts primarily on adipose tissue to reduce insulin resistance."3.72Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report. ( Bunnag, P; Prasithsirikul, W, 2004)
"Metformin was the only insulin-sensitizer to demonstrate beneficial effects on all three components of HALS."2.46The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials. ( Larson, RJ; Sheth, SH, 2010)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Okada, S1
Konishi, M1
Ishii, H1
Sheth, SH1
Larson, RJ1
Magkos, F1
Brennan, A1
Sweeney, L1
Kang, ES1
Doweiko, J1
Karchmer, AW1
Mantzoros, CS1
Calmy, A1
Hirschel, B1
Hans, D1
Karsegard, VL1
Meier, CA1
Prasithsirikul, W1
Bunnag, P1
Slama, L1
Lanoy, E1
Valantin, MA1
Bastard, JP1
Chermak, A1
Boutekatjirt, A1
William-Faltaos, D1
Billaud, E1
Molina, JM1
Capeau, J1
Costagliola, D1
Rozenbaum, W1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744]Phase 2112 participants (Anticipated)Interventional2021-08-03Recruiting
Role of Leptin in Highly Active Antiretroviral Therapy (HAART)-Induced Lipodystrophy and Metabolic Syndrome in HAART-Treated HIV Patients[NCT00140244]Phase 27 participants (Actual)Interventional2001-12-31Completed
A Randomized, Phase 3, Double Blind, Multicentre Trial, Evaluating the Effect of Pioglitazone Versus Placebo on Change in Lipoatrophy in HIV- 1 Infected Patients Treated With Stable Antiretroviral Therapy for at Least 6 Months.ANRS 113 LIPIOT Study[NCT00148850]Phase 3130 participants Interventional2003-02-28Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Blood Pressure

percent change in mean blood pressure (NCT00140244)
Timeframe: At the end of each two month intervention

Interventionpercentage change of mean blood pressure (Least Squares Mean)
r-MetHuLeptin3.2
Placebo-6.7

CD4+ Lymphocytes

(NCT00140244)
Timeframe: At the end of each two month intervention

Interventioncells/mcl (Mean)
r-MetHuLeptin556.6
Placebo637.2

Fibrinogen

Fibrinogen (NCT00140244)
Timeframe: At the end of each two month intervention

Interventionmg/dL (Mean)
r-MetHuLeptin252.2
Placebo294.4

Free Fatty Acid (FFA) Levels

(NCT00140244)
Timeframe: At the end of each two month intervention

InterventionmEq/liter (Mean)
r-MetHuLeptin0.45
Placebo0.61

Glycemia (as Assessed by Fasting Glucose)

(NCT00140244)
Timeframe: At the end of each two month intervention

Interventionmg/dl (Mean)
r-MetHuLeptin91
Placebo95.6

Hepatic Fat Content

(NCT00140244)
Timeframe: At the end of each two month intervention

Interventionpercentage of liver volume (Mean)
r-MetHuLeptin4.02
Placebo4.01

Insulin Levels

(NCT00140244)
Timeframe: At the end of each two month intervention

InterventionmcIU/ml (Mean)
r-MetHuLeptin11.6
Placebo20.3

Insulin Resistance (as Assessed by HOMA-IR)

(NCT00140244)
Timeframe: At the end of each two month intervention

Interventionunits on a scale (Mean)
r-metHuLeptin2.52
Placebo4.56

Interleukin-6 (IL-6) Levels

(NCT00140244)
Timeframe: At the end of each two month intervention

Interventionpg/ml (Mean)
r-MetHuLeptin1.65
Placebo2.14

Lean Body Mass

lean body mass (NCT00140244)
Timeframe: At the end of each two month intervention

Interventionkg (Mean)
r-MetHuLeptin58.6
Placebo61.6

Low Density Lipoprotein (LDL) Cholesterol Levels

(NCT00140244)
Timeframe: At the end of each two month intervention

Interventionmg/dl (Mean)
r-MetHuLeptin113
Placebo105.7

Viral Load

(NCT00140244)
Timeframe: At the end of each two month intervention

Interventioncopies/ml (Mean)
r-MetHuLeptin11345
Placebo12367

Serum Lipid Levels

(NCT00140244)
Timeframe: At the end of each two month intervention

,
Interventionmg/dl (Mean)
total cholesterollow density lipoprotein cholesteroltriglycerideshigh density lipoprotein cholesterolsFree fatty acids
Placebo219.7105.7520.529.960.61
r-MetHuLeptin228.8113.0409.0350.45

Reviews

1 review available for pioglitazone and HIV Lipodystrophy Syndrome

ArticleYear
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.
    BMC infectious diseases, 2010, Jun-23, Volume: 10

    Topics: Adult; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycemic Agents; Insulin Resistanc

2010

Trials

3 trials available for pioglitazone and HIV Lipodystrophy Syndrome

ArticleYear
Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.
    Metabolism: clinical and experimental, 2011, Volume: 60, Issue:7

    Topics: Adiponectin; Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Body Mass Index; Drug Ther

2011
Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy.
    AIDS (London, England), 2003, Mar-28, Volume: 17, Issue:5

    Topics: Adult; Anthropometry; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV Infectio

2003
Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113).
    Antiviral therapy, 2008, Volume: 13, Issue:1

    Topics: Adult; Double-Blind Method; Female; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hypoglycem

2008

Other Studies

2 other studies available for pioglitazone and HIV Lipodystrophy Syndrome

ArticleYear
Pioglitazone therapy for HIV/HAART-associated lipodystrophy syndrome could increase subcutaneous fat mass in non-lipoatrophic but not in lipoatrophic regions.
    BMJ case reports, 2016, Feb-25, Volume: 2016

    Topics: Antiretroviral Therapy, Highly Active; Body Fat Distribution; HIV-Associated Lipodystrophy Syndrome;

2016
Improvement of fat redistribution, insulin resistance and hepatic fatty infiltration in HIV-associated lipodystrophy syndrome by pioglitazone: a case report.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2004, Volume: 87, Issue:2

    Topics: Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Administration Sch

2004